Aisyip completed over 100 million yuan in Series B financing

Recently, Beijing Aisipu Biotechnology Co., Ltd. (“Aisipu”) announced that it has completed a Series B financing of over 100 million yuan. As a CRO enterprise focusing on the biological research of drug discovery, Aisippu takes technology to empower new drug research and development enterprises, reduce the risk of new drug research and development, improve the efficiency of new drug research and development, and reduce the cost of new drug research and development. This round of financing was led by Jifeng Capital, followed by CICC Qide Fund, Guojing Capital, Yida Capital, Longmen Capital, and Hangshi Asset Management’s funds. Old shareholders Hetang Venture Capital and Jinyu Bogor continued to make additional investments. .

After this round of financing, Aisipu will further build and improve its integrated biological service capabilities for innovative drugs from target discovery and verification, lead compound screening and optimization to preclinical candidate molecule determination.

With more than 10 years of accumulation, Aisyip has established a target library of more than 1,500 targets, which is one of the leading target libraries in China and even in the world, covering kinases and enzymology, GPCR receptors, ion channels, nuclear receptors. body, transporter and other fields. After this round of financing, AiSi Yipu will continue to deepen the layout of early drug discovery platforms, strengthen methodological development capabilities, expand new targets and new technology platforms, and comprehensively deploy small molecules, PROTACs, peptides, antibodies, ADCs and small nucleic acids. Biological technology for drug discovery and evaluation; further improve and open up target validation, protein purification, biochemical enzymology, tumor cytology, immunology, neurobiology, electrophysiology, cardiac pharmacology, central nervous system pharmacology, tumor pharmacology It provides integrated services for the research and development of innovative drugs through platforms such as science, drug off-target effect evaluation, drug cardiac safety evaluation, ADME, PK/PD and other platforms.